DHODH: A Promising Target in the Treatment of T-Cell Acute Lymphoblastic Leukemia

Authors

Amy N Sexauer
Gabriela Alexe
Karin Gustafsson
Elizabeth Zanetakos
Jelena Milosevic
Mary Ayres
Varsha Gandhi
Yana Pikman
Kimberly Stegmaier
David B Sykes

Publication Date

11-14-2023

Journal

Blood Advances

Abstract

Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) have a poor prognosis with few therapeutic options. With the goal of identifying novel therapeutic targets, we used data from the Dependency Map project to identify dihydroorotate dehydrogenase (DHODH) as one of the top metabolic dependencies in T-ALL. DHODH catalyzes the fourth step of de novo pyrimidine nucleotide synthesis. Small molecule inhibition of DHODH rapidly leads to the depletion of intracellular pyrimidine pools and forces cells to rely on extracellular salvage. In the absence of sufficient salvage, this intracellular nucleotide starvation results in the inhibition of DNA and RNA synthesis, cell cycle arrest, and, ultimately, death. T lymphoblasts appear to be specifically and exquisitely sensitive to nucleotide starvation after DHODH inhibition. We have confirmed this sensitivity in vitro and in vivo in 3 murine models of T-ALL. We identified that certain subsets of T-ALL seem to have an increased reliance on oxidative phosphorylation when treated with DHODH inhibitors. Through a series of metabolic assays, we show that leukemia cells, in the setting of nucleotide starvation, undergo changes in their mitochondrial membrane potential and may be more highly dependent on alternative fuel sources. The effect on normal T-cell development in young mice was also examined to show that DHODH inhibition does not permanently damage the developing thymus. These changes suggest a new metabolic vulnerability that may distinguish these cells from normal T cells and other normal hematopoietic cells and offer an exploitable therapeutic opportunity. The availability of clinical-grade DHODH inhibitors currently in human clinical trials suggests a potential for rapidly advancing this work into the clinic.

Keywords

Humans, Animals, Mice, Dihydroorotate Dehydrogenase, Oxidoreductases Acting on CH-CH Group Donors, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enzyme Inhibitors, T-Lymphocytes, Nucleotides

Comments

Supplementary Materials

PMID: 37648673